Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

PHASE3CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

May 29, 2014

Primary Completion Date

November 6, 2015

Study Completion Date

September 10, 2021

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Nivolumab

DRUG

Cetuximab

DRUG

Methotrexate

DRUG

Docetaxel

Trial Locations (64)

100

Local Institution - 0064, Taipei

704

Local Institution - 0065, Tainan City

1880

Local Institution - 0015, Berazategui

4000

Local Institution - 0013, San Miguel de Tucumán

5000

Local Institution - 0014, Córdoba

8091

Local Institution - 0051, Zurich

10126

Local Institution, Torino

12200

Local Institution - 0047, Berlin

15213

Local Institution - 0007, Pittsburgh

20133

Local Institution, Milan

20142

Local Institution, Milan

20246

Local Institution - 0052, Hamburg

27710

Dumc, Durham

28041

Local Institution - 0034, Madrid

30322

Local Institution - 0001, Atlanta

30625

Local Institution - 0046, Hanover

33612

H. Lee Moffitt Cancer Center, Tampa

35128

Local Institution, Padua

37232

Vanderbilt Cancer Clinic, Nashville

43210

Local Institution - 0012, Columbus

45122

Local Institution - 0048, Essen

46010

Local Institution - 0033, Valencia

47014

Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola

48109

University Of Michigan, Ann Arbor

53127

Local Institution - 0049, Bonn

53226

Local Institution - 0031, Milwaukee

60637

Local Institution - 0002, Chicago

69373

Local Institution, Lyon

70006

Local Institution - 0004, Metairie

77030

Univ Of Tx. Md Anderson, Hoston

80131

Local Institution, Napoli

84112

Huntsman Cancer Institute, Salt Lake City

94305

Stanford University Medical Center, Stanford

94805

Local Institution, Villejuif

97070

Local Institution - 0050, Würzburg

2778577

Local Institution - 0060, Kashiwa

4118777

Local Institution - 0059, Sunto-gun

4648681

Local Institution - 0056, Nagoya

5698686

Local Institution - 0063, Takatsuki

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

98700-000

Local Institution - 0054, Ijuí

90610-000

Local Institution, Porto Alegre

01321-001

Local Institution - 0055, São Paulo

V5Z 4E6

Local Institution - 0038, Vancouver

N6A 4L6

Local Institution - 0045, London

06189

Local Institution, Nice

Unknown

Local Institution, Hong Kong

0608648

Local Institution - 0062, Sapporo

650-0017

Local Institution - 0058, Kobe

673-8558

Local Institution - 0057, Akashi, Hyogo

135-8550

Local Institution - 0061, Tokyo

1081 HV

Local Institution, Amsterdam

9713 AP

Local Institution, Groningen

2333 ZA

Local Institution, Leiden

135-710

Local Institution - 0067, Seoul

137-701

Local Institution - 0066, Seoul

08035

Local Institution - 0032, Barcelona

08036

Local Institution - 0035, Barcelona

SW3 6JJ

Local Institution, London

M20 4BX

Local Institution, Manchester

SO16 6YD

Local Institution, Southampton

CH63 4JY

Local Institution, Metropolitan Borough of Wirral

SM2 5PT

Local Institution, Surrey

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY